Journal Title
Title of Journal: Curr Colorectal Cancer Rep
|
Abbravation: Current Colorectal Cancer Reports
|
|
|
|
|
|
|
|
Authors: Nele Boeckx Ken Op de Beeck Vanessa Deschoolmeester Guy Van Camp Patrick Pauwels Marc Peeters
Publish Date: 2014/08/22
Volume: 10, Issue: 4, Pages: 380-394
Abstract
AntiEGFR therapy in metastatic colorectal cancer mCRC has improved survival outcome However many patients do not respond to this therapy and almost all patients develop resistance after a few months of treatment Since 2008 the therapy has been restricted to patients without mutations in KRAS an important target in the EGFR pathway as these patients do not benefit from antiEGFR therapy Recently this has been changed to an allRAS wildtype strategy Despite these restrictions still 40 to 60 of mCRC patients are resistant New biomarkers need to be identified in order to improve patient selection Another problem is tumor heterogeneity which impedes the detection of mutations in resistance genes and can consequently lead to wrong treatment decisions A possible solution for this problem may be found in liquid biopsies In this review known and promising upcoming biomarkers associated with resistance to antiEGFR therapy will be summarized Moreover the potential added value of liquid biopsies in patient selection and followup will be discussedNele Boeckx Ken Op de Beeck Vanessa Deschoolmeester and Guy Van Camp declare that they have no conflict of interest Patrick Pauwels has received compensation from Amgen and Merck Serono for service as a consultant Marc Peeters has received compensation from Amgen Merck Serono Sanofi and Roche for service as a consultant
Keywords:
.
|
Other Papers In This Journal:
|